207_Combined course Presentations

ACCORD 12/0405

CAO/ARO/ AIO-04

NSABP R-04

STAR-01

PETACC-6

Endpoint

PCR

16% both arms 4% vs 7%

14% vs 19%

12.8% vs 16.5% (p=0.038)

19% vs 21%

11.5% vs 13%

CRM

8% vs 13%

5% vs 6% No

2% vs 2%

data

Node + (stage III)

29% vs 26%

30% vs 26%

27% vs 26%

Not stated

27% vs 26%

Oxaliplatin Phase III trials: Control arm in red